Cargo therapeutics inc CRGX.US 總覽分析
CRGX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
CRGX 近期報酬表現
-1.14%
Cargo therapeutics inc
3.56%
同產業平均
1.47%
S&P500
與 CRGX 同產業的標的表現
- BIOA Bioage labs inc價值 -趨勢 3 分波段 4 分籌碼 2 分股利 1 分查看更多
CRGX 公司資訊
CARGO Therapeutics, Inc. is a biotechnology company focused on the development of best-in-class and potentially curative cell therapies for cancer patients. It has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a range of B-cell malignancies with the goal of providing more patients with a durable complete response. Its latest program advancement, an allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer.